CL5D Applied to Protein Oligomerization: Corrigendum to Paper 6 and Four Propositions Beyond AlphaFold pLDDT
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Sprache: | Englisch |
| Veröffentlicht: |
Zenodo
2026
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866901255385776128 |
|---|---|
| author | Chakraborty, Mrinmoy |
| author_facet | Chakraborty, Mrinmoy |
| contents | <p><strong>This combined paper presents two contributions to the CL5D Research Series. Paper 6 v2.0 is a formal corrigendum to Paper 6 (doi:10.5281/zenodo.19043350), correcting three errors: (C1) overclaim of "100% precision in silico," (C2) dismissal of biological stochasticity, and (C3) inappropriate comparison with AlphaFold structural accuracy. The corrected CL5D pipeline (At→Ab→Ex→T→Cn) is applied to PDB structures 6EJ2 (BACE1, Alzheimer) and 2V5Z (MAO-B, Parkinson) under the genomics domain protocol (no 50% gate), yielding Cn = 0.017612 and 0.014417 respectively (both Excellent, Phase I). Paper 10 establishes four propositions demonstrating that CL5D Cn scores provide phase-dynamic information that pLDDT cannot: phase transition trajectories (P1), drug binding site readiness (P2), oligomeric state classification (P3), and disordered region functional roles (P4). All propositions are validated against PDB experimental data. Benchmark BS = 0.00002 (fixed).</strong></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_19176903 |
| institution | Zenodo |
| language | eng |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | CL5D Applied to Protein Oligomerization: Corrigendum to Paper 6 and Four Propositions Beyond AlphaFold pLDDT Chakraborty, Mrinmoy CL5D Hybrid Model Cn Score pLDDT BACE1 MAO-B Phase Transition Drug Binding Oligomeric State Disordered Regions Genomics Corrigendum AlphaFold <p><strong>This combined paper presents two contributions to the CL5D Research Series. Paper 6 v2.0 is a formal corrigendum to Paper 6 (doi:10.5281/zenodo.19043350), correcting three errors: (C1) overclaim of "100% precision in silico," (C2) dismissal of biological stochasticity, and (C3) inappropriate comparison with AlphaFold structural accuracy. The corrected CL5D pipeline (At→Ab→Ex→T→Cn) is applied to PDB structures 6EJ2 (BACE1, Alzheimer) and 2V5Z (MAO-B, Parkinson) under the genomics domain protocol (no 50% gate), yielding Cn = 0.017612 and 0.014417 respectively (both Excellent, Phase I). Paper 10 establishes four propositions demonstrating that CL5D Cn scores provide phase-dynamic information that pLDDT cannot: phase transition trajectories (P1), drug binding site readiness (P2), oligomeric state classification (P3), and disordered region functional roles (P4). All propositions are validated against PDB experimental data. Benchmark BS = 0.00002 (fixed).</strong></p> |
| title | CL5D Applied to Protein Oligomerization: Corrigendum to Paper 6 and Four Propositions Beyond AlphaFold pLDDT |
| topic | CL5D Hybrid Model Cn Score pLDDT BACE1 MAO-B Phase Transition Drug Binding Oligomeric State Disordered Regions Genomics Corrigendum AlphaFold |
| url | https://doi.org/10.5281/zenodo.19176903 |